- Raised Pre-Seed round, Apr 2025
- Raised grant
About
ReSynapse Therapeutics is a biotechnology company developing selective multi-target small molecules for treatment-resistant depression and anxiety disorders. The company utilizes computational drug design and AI-driven drug design platforms to identify compounds that precisely modulate multiple serotonin receptors simultaneously, aiming for faster onset, improved efficacy, and favorable safety profiles. Their approach focuses on targeting specific combinations of 5-HT receptors for each indication. ReSynapse is a precision neuroscience company aiming to create fast-acting, long-lasting therapeutics that address critical unmet needs in depression and anxiety. They develop a novel class of multi-target compounds for serotonin (5-HT) receptors modulation. The solution integrates complex mechanisms of action of the serotonergic system with AI-driven structural biology to design compounds targeting multiple serotonin receptor subtypes, optimizing therapeutic outcomes.
Funding history · 2 rounds · — total
Headcount over time
Q&A
- What is ReSynapse Therapeutics' primary focus?
- ReSynapse Therapeutics is a biotechnology company developing selective multi-target small molecules for treatment-resistant depression using computational drug design.
- What is ReSynapse Therapeutics' current employee count?
- ReSynapse Therapeutics has 1-10 employees.
- When was ReSynapse Therapeutics founded?
- ReSynapse Therapeutics was founded in December 2024.
- What is ReSynapse Therapeutics' current funding stage?
- ReSynapse Therapeutics is currently in the Pre-Seed funding stage.
- What is the estimated market size for treatment-resistant depression that ReSynapse Therapeutics is targeting?
- The market for treatment-resistant depression is estimated at $1.9 billion, covering 2.8 million Americans and 11 million Europeans.
- What is ReSynapse Therapeutics' approach to drug design?
- ReSynapse Therapeutics designs single molecules that modulate specific combinations of serotonin receptors using mechanism-based computational chemistry, integrating structural biology and pharmacological understanding.
- What is the expected timeline for ReSynapse Therapeutics' IP filing and POC validation?
- ReSynapse Therapeutics expects IP filing in Q1 2026 and POC validation in Q3-Q4 2026.
- Who is a founder of ReSynapse Therapeutics?
- Dorit Cohen Carmon is a founder of ReSynapse Therapeutics.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | resynapse.carrd.co/ |
|---|---|
| linkedin.com/company/resynapse-therapeutics/ |
Identifiers & details
| Legal name | RESYNAPSE THERAPEUTICS LTD |
|---|---|
| Founded | 2025-5 |
| Employees (exact) | 5 |
Radar intelligence
Web history (Wayback)
| Domain | resynapse.carrd.co |
|---|
Certificate / subdomain footprint
| Subdomains | 0 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 517161493 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2025-05-12 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | אבנר בן נר 16 נס ציונה |